Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Cash from Operations (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Cash from Operations for 6 consecutive years, with 4210000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations fell 0.55% to 4210000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 14440000.0, a 15.97% decrease, with the full-year FY2024 number at 12691000.0, down 6.65% from a year prior.
  • Cash from Operations was 4210000.0 for Q3 2025 at Vivos Therapeutics, down from 3494000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 2516000.0 in Q1 2024 to a low of 6082000.0 in Q1 2022.
  • A 5-year average of 3759263.16 and a median of 3700000.0 in 2021 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: crashed 792.63% in 2021, then skyrocketed 52.44% in 2023.
  • Vivos Therapeutics' Cash from Operations stood at 4122000.0 in 2021, then grew by 26.9% to 3013000.0 in 2022, then rose by 10.39% to 2700000.0 in 2023, then fell by 8.89% to 2940000.0 in 2024, then plummeted by 43.2% to 4210000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Cash from Operations are 4210000.0 (Q3 2025), 3494000.0 (Q2 2025), and 3796000.0 (Q1 2025).